Posts Tagged ‘vaccine’
Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC), a CSC Company (NYSE:CSC), presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives…
AmpVacs A Broadly Protective Synthetic Influenza A Vaccine
Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats…
Dynavax Selects Clinical Candidate In Universal Flu Vaccine Program
Dynavax Technologies Corporation (NASDAQ: DVAX) announced that it has selected a clinical vaccine candidate for its novel Universal Flu program, completed key preclinical studies, and is reviewing clinical plans with the FDA in anticipation of initiating a Phase I study by mid-year…
FDA Recommends H1N1 For Inclusion In Next Year’s Flu Vaccine
The U.S. Food and Drug Administration (FDA) on Monday recommended that the H1N1 (swine flu) strain be added to next year’s seasonal flu vaccine, “putting an end to separate shots deployed against the pandemic,” Bloomberg reports. The FDA committee voted unanimously to make the H1N1 strain one of the three strains included in the shot, according to the news service…
SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
Bharat Biotech Begins Phase I Clinical Trials Of HN-VAC – Its Cell Culture H1N1 Vaccine
Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials…
VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine To Biological E.; Vaccine Could Become Available For Use In India This Year
VaxInnate Corporation announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India…
SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
Canada To Bridge Mexico’s H1N1 Flu Vaccine Requirements
The Honourable Leona Aglukkaq, Minister of Health, on behalf of the Government of Canada, has announced it will be providing five million doses of H1N1 flu vaccine to Mexico to help bridge that country’s immediate pandemic vaccine requirements. This is not a donation. Mexico will replenish Canada’s H1N1 vaccine supply by March 31, 2010…
Experts On Vaccine Advisory Panels Had Conflicts, CDC Report Says
Sixty-four percent of the advisers hired by the Centers for Disease Control and Prevention in 2007 to serve on panels evaluating cervical cancer and flu vaccines had potential conflicts of interest that were unresolved or were not identified by the agency, according to a new report by HHS Inspector General Daniel Levinson, the New York Times reports…
Rx Drug Compare
Translator
By N2H